Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 14Completed 4Active not recruiting 3Suspended 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 52Neoplasms 36Colorectal Neoplasms 33Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 30Pancreatic Neoplasms 21Multiple Myeloma 16Recurrence 14Ovarian Neoplasms 14Uterine Cervical Neoplasms 12Leukemia, Myeloid, Acute 11Carcinoma, Hepatocellular 11Neoplasm Metastasis 10Head and Neck Neoplasms 10Brain Neoplasms 10Melanoma 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 8Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Glioblastoma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Glioma 6Esophageal Neoplasms 6Colonic Neoplasms 6

Interventions

selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Myeloproliferative Disorders × 30 days × Clear all
NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Zhongshan Hospital (Xiamen), Fudan University

Phase 2 Not yet recruiting
15 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡